Lesinurad: Phase III data

Top-line data from the double-blind, placebo-controlled, U.S. Phase III CLEAR1 trial in 603 symptomatic gout patients not achieving target sUA levels on their current allopurinol dose showed that once-daily 200 and 400 mg lesinurad plus allopurinol each met the primary endpoint of improving the proportion of patients achieving target sUA levels of <6 mg/mL at month 6 vs. allopurinol alone (p<0.0001 for both). The most common adverse events reported with lesinurad plus allopurinol were upper respiratory tract infection, nasopharyngitis and back pain. Patients who complete the trial have the option to receive 200 and 400 mg lesinurad plus allopurinol in an open-label extension study. ...